The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of Foxy-5 in patients with metastatic breast, colorectal, or prostate cancer.
Peter Grundtvig Soerensen
Research Funding - WatResearch
Tommy Andersson
Employment or Leadership Position - WntResearch
Stock Ownership - WatResearch (I); WntResearch
Research Funding - WntResearch
Ulla Buhl
Employment or Leadership Position - WntResearch (I); WntResearch
Stock Ownership - WatResearch (B)
Tine Moelvadgaard
Employment or Leadership Position - Smerud Medical Research
Peter Buhl Jensen
Employment or Leadership Position - WntResearch (B)
Stock Ownership - WntResearch (B)
Nils Brunner
Employment or Leadership Position - WatResearch
Stock Ownership - WntResearch
Dorte Nielsen
Consultant or Advisory Role - WntResearch